{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:04:20Z","timestamp":1784019860560,"version":"3.55.0"},"reference-count":147,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The treatment landscape of oncogene-driven non-small-cell lung cancer (NSCLC) has evolved substantially with the development of targeted therapies directed against actionable molecular alterations. Tyrosine kinase inhibitors (TKIs) remain the cornerstone of treatment for many driver-defined subsets; however, acquired resistance, central nervous system progression, and tumor heterogeneity continue to limit long-term disease control. This review examines the mechanistic foundations, clinical evidence, resistance patterns, and emerging therapeutic roles of TKIs, antibody\u2013drug conjugates (ADCs), and bispecific antibodies (bsAbs) in oncogene-driven NSCLC. Relevant preclinical studies, clinical trials, and recent therapeutic advances across major actionable driver alterations were reviewed and compared. TKIs provide potent and selective inhibition of oncogenic signaling and remain the preferred frontline therapy in most molecular subgroups, whereas ADCs offer targeted payload delivery that may overcome diverse resistance mechanisms, and bsAbs provide dual-target blockade and immune-mediated antitumor activity. Emerging evidence supports the expanding role of ADCs and bsAbs in post-TKI settings and selected biomarker-defined populations. Resistance mechanisms differ across therapeutic classes and include secondary target alterations, bypass pathway activation, antigen loss, payload resistance, and receptor adaptation. Collectively, these modalities are increasingly being integrated into biomarker-guided treatment strategies, with future management likely to rely on rational sequencing and combination approaches tailored to resistance mechanisms, target expression, central nervous system involvement, and tumor heterogeneity.<\/jats:p>","DOI":"10.3390\/ijms27146251","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:04:31Z","timestamp":1784016271000},"page":"6251","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tyrosine Kinase Inhibitors, Antibody\u2013Drug Conjugates, and Bispecific Antibodies in Oncogene-Driven Non-Small-Cell Lung Cancer: Evolving Roles in Treatment Sequencing and Resistance Management"],"prefix":"10.3390","volume":"27","author":[{"given":"Saba","family":"Musleh Ud Din","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2156-8917","authenticated-orcid":false,"given":"Amy","family":"Kiamos","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundas","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meri Muminovic","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2669-5771","authenticated-orcid":false,"given":"Luis E.","family":"Raez","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Memorial Healthcare System, 703 North Flamingo Road, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref_1","first-page":"CD013453","article-title":"Targeted therapy for advanced anaplastic lymphoma kinase ALK-rearranged non-small cell lung cancer","volume":"1","author":"Cameron","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Deng, L., Li, J., Qiu, Z., and Wang, Y. (2024). Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics. Front. Genet., 15, Erratum in Front. Genet.\u00a02026, 17, 1794164. https:\/\/doi.org\/10.3389\/fgene.2026.1794164.","DOI":"10.3389\/fgene.2026.1794164"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/atm-25-34","article-title":"Advances in personalized medicine: Translating genomic insights into targeted therapies for cancer treatment","volume":"13","author":"Jamalinia","year":"2025","journal-title":"Ann. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1200\/JCO-25-02822","article-title":"Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, 2026.3.0","volume":"44","author":"Puri","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103119","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S1470-2045(16)30123-1","article-title":"Novel therapeutic targets on the horizon for lung cancer","volume":"17","author":"Tan","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Liu, X., Deng, J., Zhang, R., Xing, J., Wu, Y., Chen, W., Liang, B., Xing, D., Xu, J., and Zhang, M. (2023). The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1335252"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3892\/ol.2025.15121","article-title":"EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review)","volume":"30","author":"Tian","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jcpt.13489","article-title":"Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis","volume":"47","author":"Li","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2024.5218","article-title":"Targeting CNS Metastases in Non-Small Cell Lung Cancer with Evolving Approaches Using Molecular Markers: A Review","volume":"11","author":"Malhotra","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40265-022-01698-z","article-title":"Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer","volume":"82","author":"Shah","year":"2022","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105583","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kondrashov, A., Sapkota, S., Sharma, A., Riano, I., Kurzrock, R., and Adashek, J.J. (2023). Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082160"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","article-title":"Antibody-drug conjugates (ADCs): \u201cSmart Missiles\u201d targeting cancer therapy","volume":"257","author":"Yao","year":"2026","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102922","DOI":"10.1016\/j.ctrv.2025.102922","article-title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","volume":"135","author":"Geraud","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e202500262","DOI":"10.1002\/cmdc.202500262","article-title":"Linker Design for the Antibody Drug Conjugates: A Comprehensive Review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"189550","DOI":"10.1016\/j.bbcan.2026.189550","article-title":"Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan","volume":"1881","author":"Xie","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105019","DOI":"10.1016\/j.critrevonc.2025.105019","article-title":"Trastuzumab deruxtecan: Redefining precision oncology across HER2-driven cancers","volume":"217","author":"Jalali","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104979","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1001\/jamaoncol.2022.4175","article-title":"An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)","volume":"8","author":"Prat","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: Practical considerations","volume":"62","author":"Verrazzo","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhang, S., Ye, C., Zhu, J., Wang, M., and Xu, Y. (2026). A real-world study of adverse event profiles associated with the four key components of antibody-drug conjugates based on the FAERS database. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1702195"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10555-026-10344-z","article-title":"Antibody-drug conjugates in cancer therapy: Do we need biomarkers? A comprehensive review","volume":"45","author":"Lei","year":"2026","journal-title":"Cancer Metastasis Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials","volume":"18","author":"Tan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105158","DOI":"10.1016\/j.critrevonc.2026.105158","article-title":"Trastuzumab deruxtecan in non-breast solid tumors: Expanding indications, efficacy, and future directions","volume":"220","author":"Ghidini","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e20503","DOI":"10.1200\/JCO.2026.44.16_suppl.e20503","article-title":"Real-world pharmacovigilance analysis for antibody drug conjugates (ADCs) in treatment of solid tumor malignancies","volume":"44","author":"Alhushki","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gallina, M., Carollo, A., Gallina, A., Cutaia, S., Rizzo, S., and Provenzani, A. (2025). Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050608"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"108066","DOI":"10.1016\/j.phrs.2025.108066","article-title":"Antibody-drug conjugates: A new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer","volume":"223","author":"Deng","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"oyaf331","DOI":"10.1093\/oncolo\/oyaf331","article-title":"Antibody drugs conjugates in non-small cell lung cancer: Current status and challenges","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1208\/s12248-021-00584-y","article-title":"Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor","volume":"23","author":"Bussing","year":"2021","journal-title":"AAPS J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/dmd.119.089276","article-title":"Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells","volume":"48","author":"Sharma","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s11912-024-01576-9","article-title":"Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review","volume":"26","author":"Mathiot","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2543107","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer with or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials","volume":"8","author":"Janne","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(25)00465-6","article-title":"Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): A multicentre, single-arm, phase 2 trial","volume":"26","author":"Fuereder","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103083","DOI":"10.1016\/j.ctrv.2025.103083","article-title":"Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?","volume":"143","author":"Cheo","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103960","DOI":"10.1016\/j.critrevonc.2023.103960","article-title":"Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis","volume":"184","author":"Zhu","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_49","first-page":"103557","article-title":"Corrigendum to \u2018Final Analysis Results and Patient-Reported Outcomes from DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic NSCLC\u2019","volume":"21","author":"Janne","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Desai, A., Subbiah, V., Roy-Chowdhuri, S., Sheshadri, A., Deshmukh, S., and Peters, S. (2024). Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?. Cancers, 16.","DOI":"10.3390\/cancers16223753"},{"key":"ref_51","first-page":"600434","article-title":"Targeted Therapy-Induced Interstitial Lung Disease in NSCLC: Mechanisms, Clinical Signatures, and a Precision Medicine Roadmap","volume":"20","author":"Wang","year":"2026","journal-title":"Drug Des. Devel Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/OTT.S329095","article-title":"Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations","volume":"15","author":"Petrini","year":"2022","journal-title":"Onco Targets Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00262-026-04369-0","article-title":"Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer","volume":"75","author":"Yoshichika","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1080\/14796694.2025.2550927","article-title":"EGFR Exon 20 insertions in NSCLC: From biology to amivantamab, optimal treatment strategy and emerging therapeutics","volume":"21","author":"Furuya","year":"2025","journal-title":"Future Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/cas.70228","article-title":"MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity","volume":"117","author":"Sato","year":"2026","journal-title":"Cancer Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/CCO.0000000000001200","article-title":"Antibody-drug conjugates in lung cancer: Current landscape and future perspectives","volume":"38","author":"Chen","year":"2026","journal-title":"Curr. Opin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Marin-Acevedo, J.A., Pellini, B., Kimbrough, E.O., Hicks, J.K., and Chiappori, A. (2023). Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers, 15.","DOI":"10.3390\/cancers15030629"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"394","author":"Janne","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Parvaresh, H., Roozitalab, G., Golandam, F., Behzadi, P., and Jabbarzadeh Kaboli, P. (2024). Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions. Biomedicines, 12.","DOI":"10.20944\/preprints202401.0541.v1"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes from the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"104554","DOI":"10.1016\/j.critrevonc.2024.104554","article-title":"KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies","volume":"205","author":"Liguori","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: A randomised, open-label, phase 3 trial","volume":"401","author":"Johnson","year":"2023","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): A randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Uy, N.F., Merkhofer, C.M., and Baik, C.S. (2022). HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies. Cancers, 14.","DOI":"10.3390\/cancers14174155"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/PO.20.00516","article-title":"MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations","volume":"5","author":"Socinski","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib Treatment in Patients with MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_78","first-page":"100332","article-title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in Patients with RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy from the Registrational LIBRETTO-001 Phase I\/II Trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","article-title":"Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kuo, P., Elboudwarej, E., Zavodovskaya, M., Lin, K.W., Lee, C.V., Diehl, L., Patel, J., Mekan, S., and Jurgensmeier, J.M. (2025). Trop-2 expression in non-small cell lung cancer. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0321555"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A Pooled Analysis of Datopotamab Deruxtecan in Patients with EGFR-Mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients with Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","volume":"29","author":"Chon","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"109305","DOI":"10.1016\/j.lungcan.2026.109305","article-title":"Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis","volume":"214","author":"Hayashi","year":"2026","journal-title":"Lung Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105147","DOI":"10.1016\/j.critrevonc.2026.105147","article-title":"NRG1 fusions: The potential targeted treatment in non-small cell lung cancer(NSCLC)","volume":"219","author":"Zhang","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.21037\/tlcr-2025-aw-1146","article-title":"Ivonescimab: Promise or reality for advanced non-small cell lung cancer?","volume":"14","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Khosla, A.A., Jatwani, K., Singh, R., Reddy, A., Jaiyesimi, I., and Desai, A. (2023). Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101461"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1200\/JCO.2025.43.16_suppl.8565","article-title":"Analysis of genomic and immune microenvironment differences in Chinese populations: Revealing potential mechanisms of poor immunotherapy outcomes in patients with EGFR mutation and ALK fusion non-small cell lung cancer","volume":"43","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/cam4.3649","article-title":"Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer","volume":"10","author":"Shi","year":"2021","journal-title":"Cancer Med."},{"key":"ref_99","first-page":"e260017","article-title":"Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines in Oncology","volume":"24","author":"Riely","year":"2026","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: A systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7864229","DOI":"10.1155\/jimr\/7864229","article-title":"Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy","volume":"2026","author":"Bautista","year":"2026","journal-title":"J. Immunol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e70002","DOI":"10.1111\/imr.70002","article-title":"LAG Time in the Era of Immunotherapy\u2014New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene-3","volume":"330","author":"Luca","year":"2025","journal-title":"Immunol. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Roy, D., Gilmour, C., Patnaik, S., and Wang, L.L. (2023). Combinatorial blockade for cancer immunotherapy: Targeting emerging immune checkpoint receptors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1264327"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1200\/JCO.2023.41.16_suppl.9037","article-title":"Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC)","volume":"41","author":"Desai","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Ferrara, M.G., Di Noia, V., D\u2019Argento, E., Vita, E., Damiano, P., Cannella, A., Ribelli, M., Pilotto, S., Milella, M., and Tortora, G. (2020). Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers, 12.","DOI":"10.3390\/cancers12051196"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Attili, I., Corvaja, C., Spitaleri, G., Del Signore, E., Trillo Aliaga, P., Passaro, A., and de Marinis, F. (2023). New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations. Cancers, 15.","DOI":"10.3390\/cancers15205079"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.annonc.2026.02.014","article-title":"Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD","volume":"37","author":"Riess","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab Plus Lazertinib in Patients with EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results from CHRYSALIS-2 Cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Chen, W., Zhou, A., and Zhou, Y. (2025). Correction: Bispecific antibody for lung cancer: Mechanisms and clinical insights. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1656082"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Taslimi, S., Brar, K., Ellenbogen, Y., Deng, J., Hou, W., Moraes, F.Y., Glantz, M., Zacharia, B.E., Tan, A., and Ahluwalia, M.S. (2021). Comparative Efficacy of Systemic Agents for Brain Metastases from Non-Small-Cell Lung Cancer with an EGFR Mutation\/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.739765"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2017.12.011","article-title":"Current perspective: Osimertinib-induced QT prolongation: New drugs with new side-effects need careful patient monitoring","volume":"91","author":"Schiefer","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance Analysis of Cardiac Toxicities Associated with Targeted Therapies for Metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1097\/JS9.0000000000004704","article-title":"From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy","volume":"112","author":"Yu","year":"2026","journal-title":"Int. J. Surg."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/cncr.35349","article-title":"The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and\/or pneumonitis: A systematic review and single-arm meta-analysis","volume":"130","author":"Li","year":"2024","journal-title":"Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"oyaf396","DOI":"10.1093\/oncolo\/oyaf396","article-title":"Characterization of the safety profile of trastuzumab deruxtecan by dose: A pooled analysis across DESTINY studies","volume":"31","author":"Park","year":"2025","journal-title":"Oncologist"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","article-title":"Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment","volume":"85","author":"Wei","year":"2025","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"103160","DOI":"10.1016\/j.eclinm.2025.103160","article-title":"Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: A pharmacovigilance study","volume":"82","author":"Zhu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2023.02.008","article-title":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","volume":"178","author":"Park","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jtho.2025.01.018","article-title":"Preventing Infusion-Related Reactions with Intravenous Amivantamab-Results from SKIPPirr, a Phase 2 Study: A Brief Report","volume":"20","author":"Spira","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC-mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2017_16","article-title":"Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer","volume":"249","author":"Facchinetti","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","article-title":"Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort","volume":"7","author":"Iams","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Guidi, L., Pellizzari, G., Tarantino, P., Valenza, C., and Curigliano, G. (2023). Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers, 15.","DOI":"10.3390\/cancers15041130"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"101353","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug Resist. Updat."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Collins, D.M., Bossenmaier, B., Kollmorgen, G., and Niederfellner, G. (2019). Acquired Resistance to Antibody-Drug Conjugates. Cancers, 11.","DOI":"10.3390\/cancers11030394"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of Resistance to Antibody-Drug Conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/cas.70319","article-title":"Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers","volume":"117","author":"Murase","year":"2026","journal-title":"Cancer Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: From mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Moreau","year":"2024","journal-title":"Blood Adv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: Implications for novel treatment strategies","volume":"11","author":"Chari","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ejh.70168","article-title":"The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma","volume":"117","author":"Barachini","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11912-025-01655-5","article-title":"Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution","volume":"27","author":"Tawfiq","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Amoozgar, B., Bangolo, A., Habibi, M., Cho, C., and Goy, A. (2025). From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115319"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"101929","DOI":"10.1016\/j.xcrm.2025.101929","article-title":"The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC","volume":"6","author":"Oh","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e2100512","DOI":"10.1200\/PO.21.00512","article-title":"Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers","volume":"6","author":"Gouda","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-024-00797-2","article-title":"Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy","volume":"9","author":"Ding","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Zhang, S., Li, R., Cui, H., and Li, H. (2025). Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: A systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1673115"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"102572","DOI":"10.1016\/j.ctrv.2023.102572","article-title":"TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)","volume":"118","author":"Parisi","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"105093","DOI":"10.1016\/j.critrevonc.2025.105093","article-title":"TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes","volume":"218","author":"Ansab","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pccm.2022.12.001","article-title":"HER3-targeted therapeutic antibodies and antibody-drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors","volume":"1","author":"Larsen","year":"2023","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6251\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:07:36Z","timestamp":1784016456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":147,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146251"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146251","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}